Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	The Hydration Pharmaceuticals Company Limited
ABN	620 385 677

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Gretta van Riel
Date of last notice	15 December 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A	
Date of change	14 April 2022	
No. of securities held prior to change		
	Nil	
Class	Fully Paid Ordinary Shares	
Number acquired	40,000 Fully Paid Ordinary Shares	
Number disposed	N/A	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.25 per Fully Paid Ordinary Shares	

⁺ See chapter 19 for defined terms.

No. of securities held after change	
Gretta van Riel*	40,000 Fully Paid Ordinary Shares
*Securities held by Superhero Securities Limited <client a="" c=""> as nominee for Gretta van Riel</client>	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

	·
Detail of contract	N/A
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which interest related prior to	
-	
change	
Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-eash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed period

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

Were the interests in the securities or contracts	No
detailed above traded during a ⁺ closed period	
where prior written clearance was required?	
If so, was prior written clearance provided to allow	
the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.